Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kohei FujitaYuki YamamotoOsamu KanaiMisato OkamuraMasayuki HashimotoKoichi NakataniSatoru SawaiTadashi MioPublished in: Open forum infectious diseases (2020)
Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- hiv aids
- infectious diseases
- risk factors
- end stage renal disease
- adverse drug
- primary care
- ejection fraction
- newly diagnosed
- prognostic factors
- working memory
- stem cells
- dendritic cells
- immune response
- mouse model
- mesenchymal stem cells
- hepatitis c virus
- bone marrow
- patient reported